However, in the Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events after Myocardial Infarction (PARADISE-MI), ARNI was not associated with a lower incidence of death from cardiovascular causes or incident HF than ramipril among patients with AMI. The gene discussed is ACE; the disease is hydrops fetalis.